newsfilter
← Latest News
PR Newswire·

Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm

  • Kuehn Law, PLLC is investigating whether officers and directors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) breached fiduciary duties.
  • The firm alleges Soleno misrepresented or concealed significant safety concerns regarding its DCCR treatment for PWS & hyperphagia, specifically excess fluid retention.
  • Investors are told DCCR posed greater safety risks than disclosed, leading to lower commercial viability & undisclosed risks like patient discontinuation & prescriber reluctance.
  • Shareholders who purchased SLNO shares prior to March 26, 2025 are invited to contact Sophia Anne Silayan for potential legal action.
  • Kuehn Law covers all case costs & charges no fees to investor clients.